Introduction {#Sec1}
============

Bone fragility is a public health problem due to the accompanying increased morbidity, mortality, and financial costs resulting from fractures, in particular, nonvertebral and hip fractures \[[@CR1], [@CR2]\]. To reduce the burden of disease cost-effectively, methods are needed to identify persons at risk for fracture in need of treatment and persons at low risk to avoid unnecessary treatment. The most common approach used to assess fracture risk is measurement of femoral neck (FN) areal bone mineral density (aBMD) using dual-energy X-ray absorptiometry (DXA) \[[@CR3]\]. Although a lower aBMD is associated with higher fracture rates, most fractures occur in women without osteoporosis as defined by the diagnostic threshold of an FN aBMD T-score of 2.5 or more standard deviations (SD) below the young normal mean \[[@CR4], [@CR5]\].

To address this lack of sensitivity, the World Health Organization (WHO) developed the Fracture Risk Assessment Tool (FRAX) which calculates the 10-year probability of a major osteoporotic fracture based on a combination of clinical risk factors and FN aBMD. This tool has improved the identification of persons at risk of fracture in some, but not all, cohorts \[[@CR6]--[@CR8]\]. Both aBMD and FRAX identify persons at risk, but they do not take into account the cortical porosity, which is an important determinant of bone strength \[[@CR9], [@CR10]\].

Although both cortical and trabecular bone contribute to bone strength, 80 % of the skeleton is cortical, 70 % of all appendicular bone loss is cortical, and 80 % of fractures in women over 65 years of age are nonvertebral \[[@CR11], [@CR12]\]. Cortical bone loss is the result of unbalanced and accelerated intracortical remodeling initiated at points upon the intracortical surface formed by the many Haversian canals traversing it. As more bone is resorbed than replaced at each remodeling site, focal enlargement of the canals occurs, adjacent canals coalesce forming giant pores when viewed in cross section \[[@CR13]--[@CR15]\]. Just as the increase in porosity increases bone fragility, several studies now demonstrate that treatment reduces porosity \[[@CR16], [@CR17]\]. Women with hip fracture have thinner and more porous cortices than controls, and they have giant pores \[[@CR13]--[@CR15]\]. Thus, as cortical bone is an important determinant of bone strength \[[@CR9]\], its deterioration should be quantified in assessing fracture risk.

Studies using high-resolution peripheral quantitative computed tomography (HR-pQCT) images of the distal radius and tibia and digital X-ray radiogrammetry of metacarpal bone have demonstrated associations between cortical porosity and fracture \[[@CR18]--[@CR20]\]. As HR-pQCT is not widely available, we examined whether cortical porosity quantified in vivo using standard CT technology, which is available in most institutions, can be used to acquire images of the cortex and its porosity. We tested the following hypotheses: (i) measurement of cortical porosity at the proximal femur, a common site of the most serious fragility fracture, is associated with nonvertebral fracture, (ii) the association between porosity and fracture is independent of aBMD and FRAX, (iii) combining measurements of porosity with aBMD or FRAX improves identification of women with fractures than any one risk assessment method alone.

Materials and methods {#Sec2}
=====================

Study design and participants {#Sec3}
-----------------------------

These hypotheses were tested in the Tromsø Study, a single-center population-based health study in Norway, which conducted six surveys in 1974, 1979--1980, 1986--1987, 1994--1995, 2001--2002, and 2007--2008, respectively \[[@CR21]\]. During the Tromsø 4 survey in 1994--1995, all 37,558 eligible inhabitants in Tromsø over 24 years were invited and 27,158 subjects (72 %) participated. All their nonvertebral fractures were registered from the x-ray archives of the University Hospital of North Norway, Tromsø between Tromsø 4 (1994--1995) and 1 January 2010 \[[@CR22], [@CR23]\].

In a nested case-control design, we identified 1250 women participating in Tromsø 4, who suffered a fracture at the hip, wrist, or proximal humerus after the age of 50 years, during the 15-year registry of fractures (1994--1995 to 2010). We invited all 760 who still were alive and living in Tromsø. We recruited 264 fracture cases after excluding premenopausal women, women with bisphosphonate exposure for osteoporosis, pathological fractures or women with hip prostheses, or metal screws in the hip region, because metal on one side can make noise in the CT images of both sides, and therefore many women with hip fractures could not be included. Age-matched fracture-free women were randomly selected among the Tromsø 4 participants, 1186 were invited, and after applying the same exclusion criteria, 260 controls were recruited. Of these 524 participants, we excluded 15 currently receiving hormone replacement therapy and 66 with movement artifacts during CT scanning. This left 443 women in the final analyses: 232 controls and 211 fracture cases (4 hip, 181 wrist, and 26 proximal humeral). The median time since their index fracture was 6.6 years. All measurements were performed from November 2011 through January 2013. All participants gave written informed consent. The study was approved by the Regional Committee of Research Ethics and the Norwegian Data Inspectorate and was conducted in accordance with the World Medical Association Declaration of Helsinki.

Procedures {#Sec4}
----------

A self-administered questionnaire included information concerning all fractures after the age of 50 years, diseases, use of medication, and lifestyle. Height and weight were measured in light clothing without shoes. Total hip and FN aBMD were measured at the nondominant side using DXA (GE Lunar Prodigy, Lunar Corporation, Madison, WI, USA), and at the opposite side in those with hip fracture at the nondominant side, and the coefficients of variation (CV) were 1.2 and 1.7 %, respectively \[[@CR24]\]. The women were categorized into those with normal FN aBMD, osteopenia, and osteoporosis using the WHO classification, and the T-score was based on the National Health and Nutrition Examination Survey (NHANES III) reference \[[@CR24]\].

The 10-year probability of a major osteoporotic fracture was calculated using the country-specific WHO FRAX algorithm for Norwegian women, including age, height, weight, parental hip fracture, rheumatoid arthritis, smoking, alcohol intake, glucocorticoid therapy, and FN aBMD \[[@CR6]--[@CR8]\]. The nonvertebral fractures used as inclusion criteria of this study were not included as "previous" fracture in the calculation of the FRAX score, as the aim was to assess 10-year probability of fracture before the event, not the probability of fracture after this event. We did include other fractures that occurred prior to the index fracture in the FRAX score, and these fractures were identified from information in questionnaires at the Tromsø 4 and the current study. FRAX is designed to be used with and without FN aBMD.

CT scans (Siemens Somatom Sensation 16, Erlangen, Germany) of the nondominant hip were performed at the Department of Radiology, University Hospital of North Norway. The CT machine had an in-plane resolution of 0.74 mm, the slice thickness was 0.6 mm, the hip was scanned from just above the femoral head to 2 cm below the lesser trochanter (Fig. [1](#Fig1){ref-type="fig"}), and the exposure dose of radiation was \~1.5 mSv. Images were analyzed in Melbourne, Australia, using StrAx1.0 software \[[@CR25]\]. As cortices are thin at the proximal femur (femoral head, neck, and trochanter), analyses were confined to a region of interest (ROI) where the cortices are thicker. This 3.7-mm subtrochanteric region starts at tip of the lesser trochanter.Fig. 1**a** Segmented computed tomography image obtained at the femoral subtrochanter using non-threshold-based image analysis, showing the total cortical area (the area used for the cortical porosity measurements); consisting of the three cortical compartments: compact appearing cortex (*green*), the outer (*white*), and inner (*red*) transitional zones, and trabecular bone area (*yellow*). **b** *Top left panel* shows entire cross section in a 63-year-old woman (subtrochanteric region) acquired using scanning electron microscopy. *Bottom Left panel* shows the same cross section downsize to simulate a resolution of 740 microns. *Top middle panel* is magnified regions of interest (ROI) at 12.5 micron resolution pores are clearly visible. *Bottom middle panel* shows the same ROI but downsized to simulate a resolution of 740 microns. Pores are no longer visible, at least not as empty pixels. *Right panels* pores which are clearly visible have been color-coded green (*top panel*). Following the downsizing of the image to simulate a resolution of 740 microns (*bottom panel*), the presence of porosity in the image signaled by the *green color* is clearly visible although it does not appear as empty pixels

The subtrochanteric region within the ROI in low resolution CT images was segmented into the compact-appearing cortex, transitional zones, and trabecular compartment using StrAx1.0, a non-thresholding method which automatically selects attenuation profile curves as reported using HR-pQCT images \[[@CR25]\]. Porosity within each cortical compartment was also quantified automatically throughout the ROI, and similarly in CT images as reported in HR-pQCT images \[[@CR25]\]. Local bone edges were identified as the beginning and the end of the rising and falling S-shaped portions of the profile curve enabling the delineation of the compartments \[[@CR25]\]. Compartments were segmented by analyzing \~3600 consecutive overlapping profiles around the perimeter of each cross-sectional slice. The density profile curve produced had two plateaus: one corresponding to the compact-appearing cortex and one corresponding to the trabecular compartment. Between these plateaus was a descending S-shaped curve or transition between the two plateaus. This was the transitional zone. The density profile curve was expressing the mineralized bone area as the percentage of total area within each column.

Porosity presented in this study is the average void volume fraction summed using all voxels within the total cortex (compact-appearing cortex, outer and inner transitional zones (Fig. [1a, b](#Fig1){ref-type="fig"})). The porosity quantified by this algorithm is the proportion of emptiness within each voxel, or the fraction of the bone volume occupied by void (porosity). The size and number of pores were not determined by using this software. However, it is common practice to be able to accurately quantify structures or objects invisible to the naked eye. To measure porosity at the subvoxel level, below visibility, two referent attenuation values are required P: the background (muscle, water etc.) and B: the fully mineralized bone matrix (1200 mg HA/cm^3^). The proportion of the voxel volume occupied by mineralized bone matrix volume is its level of fullness (LOF). As previously reported, LOF of each voxel is estimated as (LOF) % = (A~i~-P)/(B-P), where A~i~ is the attenuation of voxel *i* \[[@CR25]\]. From LOF, the void volume of each voxel or level of emptiness (porosity) = 100--LOF (%) (Fig. [2](#Fig2){ref-type="fig"}). Accuracy of porosity measurements using CT, voxel size 740 microns, was validated ex vivo by testing the agreement with HR-pQCT measurements, voxel size 82 microns, of the same ROI at the femoral subtrochanteric region in 5 cadaveric specimens. The correlation between porosity of the compact appearing cortex by these methods (*R*^2^) was 0.96 (Fig. [3a](#Fig3){ref-type="fig"}). The corresponding *R*^2^ were 0.87, 0.87, and 0.94 for porosity of the outer and inner transitional zones, and the total cortex, respectively (Fig. [3b--d](#Fig3){ref-type="fig"}). As shown in the Bland-Altman plots (right panels), the error (difference between measurements by CT and HR-pQCT scanning) ranged from 0 to 10 % depending on the compartment, and agreement between both measurements exceeded 90 %. Validation of the StrAx 1.0 software analyses of the femoral subtrochanter cortical porosity, as well as all standard CT parameters in this study, was performed by repositioning and rescanning a human hip phantom 10 times, and CVs were between 0.3 and 2.3 %. This human hip phantom was delivered with the CT scanner (Siemens Somatom Sensation 16, Erlangen, Germany).Fig. 2To measure porosity, two referent attenuation values are required P: the background (muscle, water etc.) and B: the fully mineralized bone matrix (1200 mg HA/cm^3^). The proportion of the voxel volume occupied by mineralized bone matrix is its level of fullness (LOF) and is estimated as (LOF) % = (A~i~-P)/(B-P), where A~i~ is the attenuation of voxel *i*. From LOF, the void volume of each voxel or level of emptiness (porosity) = 100--LOF (%)Fig. 3*Left panels* the correlation between CT and gold standard (HR-pQCT) measurements of porosity of **a** the compact appearing cortex, **b** outer and **c** inner transitional zones, and **d** the total cortex at the femoral subtrochanter (all *p* \< 0.05). *Right panel* Bland-Altman plots of the error (difference between measurements by CT and HR-pQCT scanning) ranged from 0 to 10 %, and agreement between both measurements exceeded 90 %

Statistical analyses {#Sec5}
--------------------

All variables were normally distributed except the FRAX score. Log-transformation corrected the skewed distribution and did not change any results. Differences between cases and controls were assessed using analysis of variance and adjusted for age. Odds ratios (OR) with 95 % confidence interval (CI) for fracture were calculated using logistic regression analyses, adjusted for age, height, weight, FN aBMD, and FRAX score and expressed per one SD difference and by threshold levels. To evaluate whether the association between cortical porosity and fracture was modified by FN aBMD or FRAX score, we included interaction terms. We explored sensitivity and specificity for fracture at selected thresholds for cortical porosity as the 75th, 80th, and 90th percentile. Using the thresholds for osteoporosis (FN aBMD T score \< −2.5), FRAX score \>20 %, and cortical porosity \>80th percentile (based on all participants as reference), as potential criteria to consider intervention, we calculated the proportion of women in the fracture and control groups meeting these criteria, and the additional number of women identified when cortical porosity was included. These data are presented in Venn diagrams. Analyses were performed using SAS Software package, v9.3 (SAS Institute Inc., Cary, NC, USA) and STATA 12.0 (StataCorp, College Station, TX, USA) with *p \<* 0.05 considered significant.

Results {#Sec6}
=======

FN aBMD, FRAX, cortical porosity, and fracture {#Sec7}
----------------------------------------------

Fracture cases had lower total hip aBMD, lower FN aBMD, higher FRAX score, and higher femoral subtrochanteric cortical porosity than controls, all *p* \< 0.001 (Table [1](#Tab1){ref-type="table"}). Each SD lower total hip aBMD (OR 2.21; 1.73--2.83), each SD lower FN aBMD (OR 2.11; 1.66--2.68), each SD higher FRAX-with-aBMD (OR 2.10; 1.64--2.70), each SD higher FRAX-without-aBMD (OR 1.62; 1.29--2.02), and each SD higher cortical porosity (OR 1.71; 1.38--2.11) was associated with fracture (all *p* \< 0.001) (Fig. [4a](#Fig4){ref-type="fig"}).Table 1Characteristics in women with fractures and controlsCases (*n* = 211)Controls (*n* = 232)*p* valueAge (years)68.4 (7.7)68.3 (6.7)0.94Height (cm)162.7 (6.1)161.2 (6.6)0.01Weight (kg)68.9 (10.5)70.0 (10.8)0.28Total Hip aBMD (mg/cm^2^)854 (113)930 (115)\<0.001Femoral neck (FN) aBMD (mg/cm^2^)794 (100)860 (112)\<0.001Have normal FN aBMD, *n* (%)47 (22.3)112 (48.3)\<0.001Have osteopenia, *n* (%)146 (69.2)109 (47.0)\<0.001Have osteoporosis, *n* (%)18 (8.5)11 (4.7)0.11FRAX score with FN aBMD (%)15.1 (8.4)10.8 (4.9)\<0.001FRAX score without FN aBMD (%)16.3 (10.2)12.7 (6.2)\<0.001Femoral subtrochanteric parameters Total bone vBMD (mg HA/cm^3^)684 (113)750 (90.0)\<0.001 Cortical vBMD (mg HA/cm^3^)1025 (72.6)1059 (56.6)\<0.001 Cortical porosity (%)43.8 (4.3)41.7 (3.4)\<0.001 Trabecular bone volume/tissue volume (%)0.27 (0.02)0.27 (0.02)0.81 Alcohol intake (drinks/week)2.7 (2.5)2.8 (2.3)0.80 Currently smoking, *n* (%)29 (13.7)24 (10.3)0.26 Physical activity (h/week)2.6 (1.6)2.5 (1.7)0.42 History of previous fracture, *n* (%)54 (25.6)0 Parental history of hip fracture, *n* (%)34 (16.1)37 (16.0)0.96 Self-reported excellent/good health status, *n* (%)147 (70.3)165 (71.1)0.86 Rheumatoid arthritis, *n* (%)11 (5.2)8 (3.5)0.36 Oral corticosteroid use, *n* (%)8 (3.8)2 (0.9)0.04 Take calcium supplements, *n* (%)44 (20.9)28 (12.1)0.01 Take supplements of vitamin D, *n* (%)163 (77.3)166 (71.6)0.17Data are mean (SD) or number (%)*p* values are adjusted for age using analysis of variance*FRAX* Fracture Risk Assessment Tool for calculation of the 10-year probability of a major osteoporotic fracture, *aBMD* areal bone mineral density, *vBMD* volumetric bone mineral densityFig. 4**a** Odds ratio (OR) and 95 % confidence interval (CI) for nonvertebral fracture per each standard deviation (SD) lower in femoral neck (FN) areal bone mineral density (aBMD), each SD higher in fracture risk assessment tool (FRAX) score with BMD, each SD higher in FRAX score without BMD, each SD higher in cortical porosity, in all women. **b** OR (95 % CI) for nonvertebral fracture per each SD higher cortical porosity in women with normal femoral neck areal bone mineral density (FN aBMD, *n* = 159, 47 with fracture), osteopenia (*n* = 255, 146 with fracture) and osteoporosis (*n* = 29, 18 with fracture)

Cortical porosity is associated with fracture independent of FN aBMD and FRAX {#Sec8}
-----------------------------------------------------------------------------

Each SD higher cortical porosity was associated with fracture independent of total hip aBMD (OR 1.30; 95 % CI 1.02--1.64, *p* = 0.03) in all women combined. Each SD higher cortical porosity was also associated with fracture independent of FN aBMD in all women combined (OR 1.39; 1.11--1.74, *p* = 0.005, Fig. [4a](#Fig4){ref-type="fig"}), in subgroups of women with normal FN aBMD (OR 1.53; 0.96--2.43), *p* = 0.07, osteopenia (OR 1.32; 1.00--1.75), *p* = 0.055, but not significantly in those with osteoporosis (OR 1.46; 0.57--3.71, *p* = 0.43, Fig. [4b](#Fig4){ref-type="fig"}).

Similarly, cortical porosity was associated with fracture independent of FRAX-with-BMD in all women combined (OR 1.58; 1.27--1.97), *p* \< 0.001, in women with normal FN aBMD (OR 1.88; 1.21--2.94), *p* = 0.005, osteopenia (OR 1.40; 1.06--1.85), *p* = 0.02, but not significantly in women with osteoporosis (OR 1.48; 0.68--3.23), *p* = 0.32.

Cortical porosity was also associated with fracture independent of FRAX-without-BMD (OR 1.73; 1.40--2.15), *p* \< 0.001, Fig. [4a, b](#Fig4){ref-type="fig"}. There was no significant interaction between porosity, aBMD, FRAX-with-BMD, or FRAX-without-BMD, all *p* \> 0.20. Further adjustment for oral corticosteroid use did not change the results.

Fracture by porosity \>80th percentile, without or with osteoporosis, or FRAX \>20 % {#Sec9}
------------------------------------------------------------------------------------

Of all women with fracture, 22 % had normal FN aBMD, 69 % osteopenia, and 9 % osteoporosis (Table [1](#Tab1){ref-type="table"}). Normal FN aBMD was protective (OR 0.29; 0.19--0.43, *p* \< 0.001), osteopenia was associated with fracture (OR 3.37; 2.16--5.26, *p* \< 0.001), but osteoporosis was not significantly associated with fracture (OR 1.87; 0.86--4.07, *p* = 0.11). In all women, independent associations with fracture were observed for porosity \>80th percentile (OR 2.70; 1.63--4.47) and FRAX-with-BMD \>20 % (OR 3.28; 1.77--6.08), both *p* \< 0.001.

In the subgroup of women with normal FN aBMD, high porosity (\>80th percentile) was present in 21 % of cases and 4 % of controls and was associated with fracture (OR 6.96; 1.96--24.7, *p* = 0.003). In the subgroup of women with osteopenia, high porosity was present in 30 % of cases and 19 % of controls and was associated with fracture, but did not achieve significance at *p* \< 0.05 level (OR 1.72; 0.94--3.13, *p* = 0.08). In the subgroup of women with osteoporosis, high porosity was present in 39 % of cases and 27 % of controls but was not associated with fracture (OR 1.70; 0.33--8.67, *p* = 0.53).

Additional women with fracture identified by porosity than FN aBMD or FRAX {#Sec10}
--------------------------------------------------------------------------

Of all 211 fracture cases, only 18 women (9 %) were identified using the osteoporosis threshold, 45 women (21 %) using the FRAX-with-BMD threshold whereas high cortical porosity level identified 61 women (29 %), Fig. [5](#Fig5){ref-type="fig"}. Porosity identified 54 (26 %) women with fractures not identified by the osteoporosis threshold and 45 (21 %) women with fractures not identified by the FRAX-with-BMD threshold. Moreover, 115 (55 %) of fracture cases were not identified by any of these methods. In addition, FRAX-without-aBMD identified 56 (27 %) women with fractures. When porosity was measured, 41 (19 %) additional women with fracture were identified over that identified by FRAX-without-aBMD alone. Of 232 controls, osteoporosis was present in 5 %, high FRAX-with-BMD in 7 %, and high cortical porosity in 12 % (Fig. [5](#Fig5){ref-type="fig"}). The sensitivity at these thresholds for osteoporosis, FRAX-with-BMD, and cortical porosity was 9, 21, and 29 %, and specificity was 95, 93, and 88 % (Table [2](#Tab2){ref-type="table"}). When porosity \>80th percentile was combined with FRAX-with-BMD \>20 %, the sensitivity for fracture was 43 % and specificity was 83 %.Fig. 5Venn diagrams illustrate the number and proportion of women identified using threshold for osteoporosis (femoral neck areal bone mineral density (BMD) T-score \< −2.5), fracture risk assessment tool (FRAX) score with-BMD \>20 %, and cortical porosity \>80th percentile, **a** in 211 women with fracture and **b** in 232 controlsTable 2Sensitivity and specificity for fractures at selected thresholdsSensitivity %95 % CISpecificity %95 % CIFemoral neck aBMD T-score below −2.5 SD8.55.1--13.195.391.7--97.6FRAX-with-aBMD \>20 %21.316.0--27.593.189.0--96.0FRAX-without-aBMD \>20 %25.119.4--31.591.887.5--95.0Cortical porosity \>75th percentile33.627.3--40.583.277.7--87.8Cortical porosity \>80th percentile28.922.9--35.587.983.0--91.8Cortical porosity \>90th percentile16.111.4--21.895.392.2--97.9FRAX-with-aBMD or porosity \>80th percentile42.735.9--49.683.277.7--87.8FRAX-without-aBMD or porosity \>80th percentile44.537.7--51.580.674.9--85.5*FRAX* Fracture Risk Assessment Tool for calculation of the 10-year probability of a major osteoporotic fracture, *aBMD* areal bone mineral density

Discussion {#Sec11}
==========

We report that cortical porosity of the proximal femur was associated with nonvertebral fractures in postmenopausal women independent of aBMD and FRAX score. This was observed in women with normal aBMD and osteopenia, persons commonly regarded as being at low fracture risk. Porosity was not significantly associated with fracture in women with osteoporosis. Measurement of porosity identified 26 and 21 % additional women with fracture than identified by the osteoporosis or FRAX thresholds, respectively.

Women concerned about bone fragility but found to have aBMD in the normal and osteopenic range would often be reassured and not offered therapy even though most fractures arise from this large segment of the population \[[@CR4]\]. The observations reported here address this unmet need. Measurement of porosity is likely to improve identification of women with normal BMD or osteopenia at risk for fracture as porosity is likely to capture fracture risk not captured by the aBMD measurement.

This report suggests that proximal femoral cortical porosity measured from clinical CT images in vivo identifies 26 % additional fracture cases over that identified by FN aBMD T-score \< −2.5. Several studies demonstrate that measurement of porosity is associated with fractures and that women with osteopenia with fractures have higher cortical porosity. Most of these studies have used HR-pQCT, a method available in only a few centers around the world \[[@CR18], [@CR20], [@CR26]\]. We were unable to show an association between cortical porosity and fracture in the small group of women with osteoporosis, due to lack of statistical power. However, most of the women with osteoporosis at the femoral neck did not have high porosity. Further studies are needed to examine this question.

FRAX score was associated with fracture as in other cohorts \[[@CR6]--[@CR8]\]. However, the measurement of porosity was associated with fracture independent of FRAX, and identified 21 % additional women with fracture over that identified by FRAX-with-BMD threshold \>20 %. In settings where bone densitometry is not available, CT is usually available, and rather than using FRAX-without-BMD alone, combining this with porosity assessment appears to identify 19 % more fracture cases than identified by FRAX-without-BMD threshold \>20 %.

Although measurement of porosity improved sensitivity for fracture by identifying additional women with fracture than identified using aBMD threshold for osteoporosis or the FRAX threshold, 55 % of the fracture cases were not identified by any of these methods. Thus, improving sensitivity remains a challenge that may be met by measurement of other material and structural propertied to build an architectural risk score and by using fall characteristics. The present results do not negate the role of trabecular bone in bone fragility. Studies using HR-pQCT of the distal radius and tibia have reported trabecular vBMD associated with fracture independent of aBMD, while one study using CT of the proximal femur reported that only cortical, not trabecular, vBMD remained associated with hip fracture after accounting for aBMD \[[@CR27]--[@CR29]\]. Another study using CT of the proximal femur reported both cortical and trabecular vBMD associated with hip fractures \[[@CR30]\].

In this study, the aBMD using DXA was measured at the femoral neck, while cortical porosity was measured at the subtrochanteric region. These two sites are located near each other, but there are huge differences in site-specific biology as one site is rich in trabecular bone with a variable thickness of cortex around its perimeter, the other site consist of a thick cortex and little trabecular bone. Better understanding of this site-specific biology may improve the use of cortical porosity as an indicator of fracture risk for certain individuals.

A strength of this nested case-control study is that it is based on a general population and a validated fracture registry \[[@CR31]\]. The newly developed StrAx software for quantification of bone architecture is validated by confirming strong correlation between measurements using CT scans and HR-pQCT, the method which has been used for previous measurements of bone architecture, and by rescanning a human hip phantom using the same standard CT machines as used for the participants of the study with good reproducibility. The measurements were obtained from the proximal femur, a site of the most serious and common fragility fracture.

The study has several limitations. The retrospective case-control design may have introduced selection bias and the index fractures occurred at a median of 6.6 years before the women had their CT scans for porosity assessment. As most of the cases had wrist fractures, we showed that cortical porosity of the proximal femur is associated with wrist fracture but it remains to study how cortical porosity is associated hip fracture.

In conclusion, cortical porosity at the proximal femur is a quantifiable risk factor for fracture that captures additional elements of bone strength not captured by aBMD or FRAX. A measurement of porosity improves identification of women with nonvertebral fracture when combined with aBMD or FRAX thresholds. Measurement of porosity is likely to better identify women at increased risk for fractures and to be a clinically useful tool that helps target treatment to those in need and avoid unnecessary treatment of those who do not need it. Further research will be needed to determine the association of subtrochanteric cortical porosity with fracture risk in a prospective population study, to improve the sensitivity using other material and structural abnormalities that contribute to fracture risk, to determine treatment threshold for cortical porosity and how to best treat those with higher porosity, as they may need to be treated differently than those individuals with lower aBMD or higher FRAX score.
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